Q1 2023 Non-GAAP Operating Income

Q1 Revenues Performance % In local currency, compared to Q1 2022 |6| +12% Successful new product launches Europe Generics +9% Higher revenues across markets International Markets Generics Revenues of $3.7b +4% AUSTEDO AJOVY $170m +10% Significant growth in prescriptions $95m +35% teva

View entire presentation